APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.

Oncotarget · 2018 · PMC5837745 · PMID 29545934

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

By day 21 the combination group showed a trend towards slower tumor regrowth compared with both vehicle and docetaxel groups, and this trend was maintained at day 28.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.